Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

407
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
407
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

93
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
93
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

174
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
174
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

283
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
283
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

203
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
203
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

219
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
219

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Major Contaminants of Emerging Concern (CECs) on Soil and Associated Health Issues.

Recent advances in food, nutrition & agriculture·2026
Same author

SARS-CoV-2 Variants and Vaccine Development: A Focused Review.

Infectious disorders drug targets·2025
Same author

Simultaneous bilateral total knee arthroplasty may be safe in selected patients.

The Knee·2025
Same author

The Benign Liver EUS Optimal Core Study (BLOCs): A Prospective Randomized Multicenter Study Evaluating Wet-suction Versus Slow Pull Technique for EUS-guided Liver Biopsy.

Journal of clinical gastroenterology·2025
Same author

Multifunctional Nanomaterials: Recent Advancements in Cancer Therapeutics and Vaccines.

Indian journal of microbiology·2025
Same author

Microfluidic Systems: Recent Advances in Chronic Disease Diagnosis and Their Therapeutic Management.

Indian journal of microbiology·2025

Related Experiment Video

Updated: Aug 2, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.8K

Emerging Treatment Approaches for COVID-19 Infection: A Critical Review.

Alok Bharadwaj1, Rasanpreet Kaur1, Saurabh Gupta1

  • 1Department of Biotechnology, GLA University, Mathura, 281406, UP, India.

Current Molecular Medicine
|April 18, 2023
PubMed
Summary

This review explores novel therapeutic strategies against SARS-CoV-2, the virus causing COVID-19. It highlights drug repositioning, vaccines, and nanotechnology for effective treatment against the pandemic.

Keywords:
Peptide repurposingSARS-CoV-2antiviral medications.proteomicstherapeuticstranscriptomics

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.3K
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.8K

Related Experiment Videos

Last Updated: Aug 2, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.8K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.3K
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.8K

Area of Science:

  • Virology and Immunology
  • Drug Discovery and Development
  • Nanomedicine

Background:

  • The SARS-CoV-2 pandemic has caused significant global health and economic damage, with millions infected and deceased.
  • Current challenges include insufficient drug development and a lack of effective biological regulation against the virus.
  • COVID-19 pathogenesis involves viral infection and immune deficiency, necessitating comprehensive therapeutic approaches.

Purpose of the Study:

  • To review and analyze current and emerging therapeutic strategies for treating SARS-CoV-2 infection.
  • To categorize treatment approaches into "target virus" and "target host" strategies.
  • To evaluate the potential of novel therapeutics, including vaccines, antibodies, and nanocarriers.

Main Methods:

  • Review of existing literature on traditional and novel COVID-19 treatments.
  • Analysis of drug repositioning, vaccine development, and monoclonal antibody research.
  • Exploration of combinatorial therapy and nanotechnology applications for drug delivery.

Main Results:

  • Traditional therapeutics show limited efficacy against SARS-CoV-2.
  • Novel vaccines and monoclonal antibodies are undergoing clinical trials for effectiveness against SARS-CoV-2 and its variants.
  • Combinatorial therapy and nanotechnology-based drug delivery show promise in overcoming limitations of existing treatments.

Conclusions:

  • Urgent development of novel drugs is crucial to combat the COVID-19 pandemic.
  • Targeting both the virus and the host immune response offers a dual approach to treatment.
  • Nanotechnology presents a promising avenue for enhancing antiviral and biological therapies.